Phogen is a joint venture between the Marie Curie Cancer Care (MCCC) charity, the UK's most comprehensive cancer care organisation, and Xenova Group plc (Nasdaq: XNVA; LSE: XEN), a UK-based biopharmaceutical company focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. To date, Phogen has generated in vivo proof of principle data to support the commercial application of its technology in the field of DNA vaccination and other gene-based therapeutics. It has also developed a completely novel VP22-based platform (Vectosomes) for controlled delivery of oligonucleotides, peptides and proteins, and has entered into a number of corporate partnerships, which have provided Phogen with revenues in excess of $2m.
GeneSegues is a biopharmaceutical company built upon advanced, targeted drug delivery technology. We conduct research and early-stage development of proprietary oncology biopharmaceuticals using our ligand-directed, nanoencapsulation technology. Our two initial product candidates are antisense therapeutics for treatment of advanced head neck and prostate cancers. We are currently conducting animal experiments with our lead product candidate for head neck cancer, and in vitro experiments with our product candidate for prostate cancer. As we progress, we will seek to outlicense these therapeutic candidates to larger drug companies for later-stage development and post-approval marketing. We have shown our targeted nanoencapsulation technology can also be adapted to other commercially significant applications, such as tumor imaging and cardiovascular disease, as future business strategy may warrant. GeneSegues was founded in 1999. We are a privately-held company based in Minneapolis, Minnesota. The Company's funding includes grant awards from the National Cancer Institute, the Department of Defense, and the National Institute of Allergy and Infectious Diseases, and private investment. Our research has been presented at several national science conferences, including the American Association for Cancer Research annual conference held in Anaheim, California in April 2005.
AustarPharma, LLC is a US based pharmaceutical company located in the world pharmaceutical capital¡ªNew Jersey, where headquartered more than 70% major multinational pharmaceutical companies with their R&D center. AustarPharma is a rapidly growing pharmaceutical company engaged in pharmaceutical research and development (R&D), commercial manufacturing and marketing of pharmaceutical finished products and related healthcare products for the worldwide markets. Austarpharma primarily focuses on drug delivery technology research, new drug development as well as generic drug development for the US market.
GeneCure has developed a unique technology to effectively deliver genes into human cells, and this technology will be employed to deliver therapeutic genes into humans as treatment and / or prevention. GeneCure's platform technology for gene transfer is based on a primate lentivirus, which has the ability to efficiently transfer genes into primary human cells yet cause no harm in humans-----the major hurdle for current gene therapy protocols. One of applications for GeneCure's platform technology is to develop novel vaccine approaches for several infectious diseases and cancers. GeneCure's lead product is a therapeutic HIV-1 vaccine for HIV-1 positive patients.
Potentia Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the eye such as age-related macular degeneration. Potentia was incorporated in 2001, based on a novel technology invented by its co-founders and a business plan that won two high-profile business plan competitions, including the 2001 Harvard Business School's Business Plan Competition. In April 2003, with start-up capital raised from private investors and matched in part by the University of Louisville , Potentia commenced full-scale operations.
Aegis Therapeutics ("Aegis") is a specialty pharmaceutical company commercializing advanced patented drug delivery and protein stabilization technologies that enable the non-invasive delivery of a broad range of protein, peptide, and non-peptide macromolecular therapeutics. Our goal is to broadly enable intranasal and transmucosal delivery of peptide and protein drugs across a wide spectrum of disease categories for the world's current and future leading pharmaceutical and biopharmaceutical companies. Aegis' Intravail® absorption enhancing excipients provide exceptionally high and unmatched systemic bioavailability performance, comparable in efficiency to injection, via the intranasal and other transmucosal administration routes, delivering potent peptide, protein, and large molecule drugs that can currently only be delivered by injection. Intravail® agents are mild and non-irritating to mucosal membranes. Intravail® Advantages Include: Non-invasive delivery of protein and peptide drugs up to 30,000 Daltons with no alteration of chemical form or biological integrity; No irritation of sensitive nasal tissues; Elimination of injections for greater patient convenience and compliance; Broader clinical indications for existing peptide and protein therapeutics; Elimination of needle-stick injuries and associated health risks; Patent-life extension and product life-cycle management; Maximized value extraction from existing drug franchises - through "product proliferation"; Shortened regulatory approval times for "new route of administration" of already approved drugs; Simple homogeneous formulations compatible with routine manufacturing and dispensing processes for ease of scale-up and production. Aegis' ProTek® protein stabilization technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the structural integrity and physiological activity of many protein and peptide therapeutics. ProTek® Advantages Include: Easily manufacturable, homogeneous, stable, aqueous dosage forms for peptide or protein therapeutics; Applicability to injectable, intranasal, and other dosage forms; Reduced aggregation and immunogenicity.
PerOs is a U.S.-based biotechnology company that has developed unique formulation methods enabling oral delivery of biopharmaceutical compounds by using naturally occurring products to create a technology platform to break the barrier of bioavailability for oral delivery of complex bioactive compounds.
Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. We are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Our operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. We are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Our focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. Transave's approach aims to significantly reduce risk and enhance success in drug development by avoiding the inherent uncertainties of new chemical entities ("NCEs"). By applying our proprietary liposomal delivery technology to well-established products that have already been approved by regulatory authorities, Transave has the potential to create new, improved profiles for these agents by enabling better delivery of the compound directly to the lung via inhalation. Compared to the original compounds, the Transave liposomal technology formulations may result in a product with the following benefits:Improved pharmacokinetic and pharmacodynamic profile; Prolonged drug exposure in the lung offering the potential for improved efficacy; Reduced systemic exposure of the drug in the blood and other vital organs, potentially resulting in an improved safety profile; Less frequent dosing, resulting in more convenience and the potential for improved patient compliance, and perhaps better patient outcomes; Ability to treat different diseases than is possible with the compound in its original formulation. The actual benefits will need to be determined based on the results of well-controlled clinical trials. Transave's product pipeline is based on its proprietary liposomal technology.
Lipoxen Plc is a United Kingdom-based holding company. The Company, along with its subsidiaries, is engaged in the development of drug and vaccine delivery systems and products in the fields of protein drugs, vaccines and oncology. The Company’s three delivery technologies include PolyXen, ImuXen and VesicALL. PolyXen technology uses the biopolymer polysialic acid to prolong the active life and improve the pharmacokinetics of therapeutic peptides and proteins. ImuXen technology uses liposome-based constructs to enhance the effectiveness of deoxyribonucleic acid (DNA), protein and polysaccharide vaccines. VesicALL technology is a technology that enables the formulation of anti-cancer treatments and other drugs using liposomal entrapment. (Source: ARS)
Unigene Laboratories, Inc. (Unigene) is a biopharmaceutical company engaged in the research, production and delivery of small proteins, referred to as peptides, for medical use. The Company has a manufacturing technology for producing many peptides cost-effectively. Unigene also has oral and nasal delivery technologies that have been shown to deliver medically useful amounts of various peptides into the bloodstream. It has two operating locations, which include the laboratory research facility with administrative offices in Fairfield, New Jersey and the pharmaceutical production facility in Boonton, New Jersey. The Company's primary focus has been on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications. (Source: 10-K)
Shire Laboratories Inc. is the advanced drug delivery subsidiary of Shire Pharmaceuticals Group plc. Shire Laboratories markets its Predictive Lead Selection Technology (ProScreen â ) and Predictive Formulation Optimization Technology (OptiScreen Ò ) to the pharmaceutical industry along with its proven and patented oral controlled release formulation technologies, Microtrol Ò , Solutrol and EnSoTrol®.
http://www.biodeliverysciences.com
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company that is utilizing its licensed, owned and drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, clinically significant new formulations of proven therapeutics. The Company's drug delivery technologies include the patented BEMA (transmucosal, or applied to the inner cheek mucosa) drug delivery technology, and the patented Bioral cochleate drug delivery technology, designed for a potentially broad base of applications. BioDelivery Sciences International's lead product, BEMA Fentanyl is a treatment for cancer pain The Company's next product utilizing the BEMA technology is BEMA Buprenorphine, a treatment for moderate to severe pain conditions, which is in Phase I. BioDelivery Sciences International's lead Bioral formulation is an encochleated version of Amphotericin B, an anti-fungal treatment for systemic fungal infections. (Source: 10-K)
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transporter mechanisms. The Company focuses its development and commercialization efforts on treatments of central nervous system (CNS), disorders. Its product candidate, XP13512, is being evaluated for the treatment of restless legs syndrome (RLS), in a Phase III clinical program in the United States and has also completed a Phase IIa clinical trial for the management of post-herpetic neuralgia (PHN), in the United States. (Source: 10-K)
Mirus Bio Corporation is a biopharmaceutical company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products. Under development are RNAi gene silencing therapies based on Mirus' proprietary Dynamic PolyConjugatesÔ delivery platform and gene therapies utilizing its Pathway IVÔ delivery protocol. Commercially, Mirus markets a range of innovative transfection and labeling research reagents worldwide. Dynamic PolyConjugates ("DPC") is a targeted systemic siRNA delivery platform. Our proprietary polymer based formulation chemistry efficiently targets gene silencing complexes to specific cells. As the DPCs attach to and enter the target cells, they respond to the environmental cues provided by the cell to disassemble and release the active siRNA molecule. This unique chemistry mimics the natural viral targeting and disassembly process. This technology is currently being optimized for liver and cancer tissues, and is actively being evaluated by select partners for research and clinical indications. Pathway IV is a clinically practical procedure based upon intravenous ("IV") delivery of plasmid DNA ("pDNA") to targeted limb muscle. With blood flow temporarily occluded by a tourniquet, a DNA solution is rapidly injected into a suitable vein. This elevates the pressure within the occlusion zone, making the blood vessel wall more permeable and allowing the pDNA to migrate into the adjoining muscle cells. Blood flow is then restored to normal within a few minutes, with only mild transient affects to the vasculature. This quick, robust procedure is being used as an enabling platform that will provide first-in-class therapeutic treatments for muscular dystrophy, peripheral ischemia and other diseases. Patients with the most common muscular dystrophies, Duchenne and Becker, suffer from a genetic defect in which dystrophin protein is either poor or inadequate in their muscle cells. It affects roughly 1 of every 3500 male births. MyoDys® will treat this disease by inserting a gene encoding active dystrophin into affected muscles to delay or prevent loss of muscle function. Peripheral ischemia is a condition in which reduced blood supply to limbs causes claudication (cramping), chronic pain, and potentially loss of the limb. It is common in diabetics and the elderly, where up to 20% of those over age 70 experience intermittent claudication. Mirus' treatment is based upon delivery of a gene encoding an angiogenic factor to the affected limb, which induces revascularization of the limb. In the future, the company envisions using muscle as the host site for gene therapies that induce secretion of therapeutic proteins to treat a range of diseases, including anemia, arthritis, ALS, and cancer immunotherapeutics. Mirus R&D uniquely integrates nucleic acid delivery and chemistry, a core competency which is unmatched in the industry. This serves as the foundation for both its novel research reagents and emerging therapeutics. The company maintains advanced research programs focused on synthetic siRNA delivery, and on gene delivery to liver and other target tissues. Access to Mirus' technologies is available through strategic alliances as well as licensing in nonstrategic fields. Mirus is well positioned to be a partner of choice due to its consistent record of profitability; driven by the sales growth of its research reagents.
About Genteric, Inc. Genteric is a biotech company formed to commercialize several proprietary technology platforms that harness the body's own protein production and distribution system. Using improved, non-viral and viral gene delivery techniques, Genteric's unique approach converts genes into therapeutic proteins within the patient's salivary glands and other gastrointestinal organs. This system then distributes the therapeutic proteins to blood, using the network nature designed for that purpose. The Genteric Method will permit the in vivo production and distribution of therapeutic quantities of virtually any desired protein.
Endovasc, Inc. is a business development company focused on drug development in the areas of cardiovascular and metabolic medicine. The Company’s licenses and patents describe technological advancements related to liposomes, stent coatings, and biodegradable/resorbable prostheses (stents) for the treatment of vascular dysfunction and heart disease. The Company’s products include Liprostin and PROStent.
DelSite, Inc., formerly Carrington Laboratories, Inc., is a research-based biopharmaceutical, medical device, raw materials and nutraceutical company engaged in the development, manufacturing and marketing of carbohydrates and other natural product therapeutics. The segments of the Company are Medical Services Division, Consumer Services Division and DelSite Biotechnologies, Inc. (DelSite). The Company sells prescription and nonprescription medical products through the Medical Services Division and provides manufacturing services to customers in medical markets. The Company through the Consumer Services Division sells consumer and raw material products and provides product development and manufacturing services to customers in the cosmetic and nutraceutical markets. On July 31, 2008, DelSite announced the sale of the Carrington wound care division to Medline Industries. DelSite will no longer manufacture, sell or distribute any Carrington wound care or skin care products.
AlphaRx is developing several drug products in the therapeutic categories of Osteoarthritis and Infectious Disease. AlphaRx intends to file IND and NDA submissions with the FDA (when necessary) and license these products to other pharmaceutical companies for worldwide commercialization. The following is a list of AlphaRx's Pharmaceutical Products in the pipeline: Name Indication Delivery Route Stage Indaflex Ô Osteoarthritis Topical Phase II Streptomycin NDS Ô Tuberculosis Oral Preclinical Zysolin Ô Infection Parenteral Preclinical
Holidays - Sonus provides the following holidays: President's Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and the day after, and Christmas Day through New Year's Day. Vacation - Vacation accrual begins with the first day of employment. Accrual rate for full-time employees is 3 weeks (15 days) per year, and for employees with more than 5 years of service, the accrual rate increases to 4 weeks (20 days) per year. The accrual rate is prorated for part-time employees. Sick Time/Leave of Absence - Full-time regular employees may be eligible for salary continuation benefits for short-term absences due to illness or injury.
PowderJect is the world's leading independent vaccine company. The company's headquarters are located in Oxford, UK, and it has facilities located in Europe and the US. With a range of products sold under its Evans Vaccines and SBL Vaccines brands, PowderJect is one of the world's largest vaccines companies. PowderJect's portfolio of products includes vaccines for influenza, yellow fever, travel diarrhoea (ETEC), cholera, tuberculosis, polio and tetanus. The company's biologicals manufacturing facilities are amongst the largest in Europe, and have approvals from both the US and European regulatory authorities. PowderJect's technology focus is on the needle-free powder injection of vaccines, a field in which it leads the world. The company is developing a broad range of vaccines based upon this proprietary delivery technology. PowderJect is also the world leader in the field of DNA vaccines, a revolutionary new method of vaccination that offers the potential to protect against and treat diseases such as hepatitis B and HIV.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory